Entering text into the input field will update the search result below

More on St. Jude Medical Q1: Net profit +11.7%; FY guidance soft

Apr. 16, 2014 7:57 AM ETSt. Jude Medical, Inc. (STJ) StockBy: Yigal Grayeff, SA News Editor
  • St. Jude Medical (NYSE:STJ) Q1 net profit $249M vs $223M.
  • Constant currency sales +4%.
  • Sales breakdown: Cardiac Rhythm Management (CRM) +1% to $687M, with U.S. ICD sales +5%; Atrial Fibrillation (AF) +8% to $251M; Cardiovascular -1% to $326M; Neuromodulation flat at $99M.
  • Outlook: Q2 adjusted EPS of $0.99-1.01 vs consensus of $1 and revenues of $1.38-1.46B vs $1.44B; FY EPS of $3.95-4.00 vs $4.30 and revenue of $5.61-5.76B vs $5.96B.
  • St. Jude expects four new CRM product approvals in the U.S. to accelerate sales in H2. (PR)
  • Previous

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
STJ--
St. Jude Medical, Inc.